The real pros and cons of Mounjaro: what clinical evidence actually shows

The strongest evidence in its favour: what the trial results tell you

When people search for the pros and cons of Mounjaro, the results column tends to dominate any honest assessment. In SURMOUNT-1 (a 72-week trial involving 2,539 adults with obesity but without type 2 diabetes) participants taking the 15mg maintenance dose lost around 20–21% of their body weight on average alongside a reduced-calorie diet and increased activity. Those are larger reductions than any other single licensed weight-loss medicine has produced in head-to-head testing: in the SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. NICE reviewed this body of evidence and recommended tirzepatide for eligible adults on the NHS, published as NICE Technology Appraisal TA1026.

Beyond weight reduction, the dual mechanism (activating both GIP and GLP-1 receptors) appears to influence blood sugar, appetite signalling and gastric emptying simultaneously. That dual action is the reason tirzepatide sits in a different pharmacological category from semaglutide, which targets only the GLP-1 pathway. For a fuller picture of how the mechanism translates into outcomes, the Mounjaro overview page covers this in more depth.

Once-weekly dosing is a practical advantage most people appreciate. A single injection (into the abdomen, thigh or upper arm) means treatment fits around a working week without daily reminders. The KwikPen design is pre-filled and disposable, so there is no drawing up of doses.

The genuine drawbacks: side effects, titration and the slow start

The cons of Mounjaro deserve the same honesty. Gastrointestinal side effects are the most common reason people find the first weeks uncomfortable: nausea, loose stools, constipation, indigestion and burping all appear in the trial data and on the NHS tirzepatide medicines page. For most people these are mild to moderate and ease as the body adjusts, but they can be disruptive around dose increases.

The titration schedule is deliberately slow. Treatment starts at 2.5mg, a dose whose primary job is helping your system acclimatise rather than producing weight loss. Progression to therapeutic doses typically happens in four-week steps, which means it can take several months before you reach the dose range where the trial results were achieved. Some people find that frustrating, particularly when they have read about the headline figures.

Pancreatitis is a less common but serious risk. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis across GLP-1 medicines: severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. This is not a reason to avoid treatment for most people, but it is a risk that your prescriber weighs at assessment.

There are also people for whom Mounjaro is not suitable at all: it is not licensed for under-18s, is not recommended during pregnancy, breastfeeding or when trying to conceive, and requires careful consideration in people with a personal or family history of certain thyroid conditions or pancreatitis.

Cost and access: the practical reality in the UK

Access is its own category in the pros-and-cons ledger. On the NHS, tirzepatide is being introduced in phases: Cohort 2 of the rollout (BMI 35–39.9 with four or more qualifying conditions) was activated in June 2026, and further cohorts are planned. For many people those criteria remain out of reach, or the waiting lists are long. A full breakdown of the NHS phases is on the Mounjaro eligibility page.

Private treatment is the alternative, and Mounjaro's UK pricing shifted significantly from September 2025 when Eli Lilly raised the list price across doses, reported private costs now range roughly £149–£375 per four-week pen depending on dose and provider. That is a real financial commitment over months of treatment, and it is worth reading the detail of what any quoted price actually includes: whether a consultation fee, prescription charge and aftercare support are bundled in or charged separately. At nume, one transparent price covers everything; there are no subscriptions and no automatic renewals, and every repeat order goes back to a prescriber for a fresh clinical review before dispatch.

If you want to see how people on treatment in the UK describe the day-to-day experience (what it actually feels like to move through the dose schedule) the Mounjaro UK forums roundup collates common themes. Worth reading before you start, rather than after your first dose increase.

Making the decision: what the consultation is actually for

No list of pros and cons can tell you whether Mounjaro is right for you specifically. The clinical assessment matters because your medical history, current medicines, BMI and any existing conditions all affect both suitability and the likely balance of benefit and risk. For women on the oral contraceptive pill, for instance, UK guidance recommends adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because absorption may be affected, a detail that rarely appears in the headline summaries.

Our prescribers at nume review every consultation personally, a real clinician reads your answers, not a piece of software making automated decisions. Once approved, the pen arrives via DPD the next working day in plain, unbranded packaging, with tracking to your phone. If you have questions as you go, the aftercare team is available seven days a week. To find out whether Mounjaro is clinically suitable for you, check your eligibility with a free consultation.